-
1 day ago | 
dukecountry.fm | Julie Steenhuysen |Amina Niasse
By Julie Steenhuysen and Amina NiasseCHICAGO (Reuters) -Health Secretary Robert F. Kennedy Jr.’s intervention in COVID-19 vaccine recommendations without input from a key U.S. CDC advisory panel has sown confusion among physicians and insurers over who should get the shots and whether they will be covered, experts told Reuters.
-
1 day ago | 
reuters.com | Julie Steenhuysen |Amina Niasse
Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021.
-
1 day ago | 
ca.news.yahoo.com | Julie Steenhuysen |Amina Niasse
CHICAGO (Reuters) -Health Secretary Robert F. Kennedy Jr.'s intervention in COVID-19 vaccine recommendations without input from a key U.S. CDC advisory panel has sown confusion among physicians and insurers over who should get the shots and whether they will be covered, experts told Reuters. Kennedy, a long-time vaccine skeptic, in a video posted on social media last week said the government was dropping its recommendation that healthy children and pregnant women should receive COVID shots.
-
1 day ago | 
today.westlaw.com | Ahmed Aboulenein |Amina Niasse |Michael Erman |Bill Berkrot
CHICAGO (Reuters) -Health Secretary Robert F. Kennedy Jr.'s intervention in COVID-19 vaccine recommendations without input from a key U.S. CDC advisory panel has sown confusion among physicians and insurers over who should get the shots and whether...
-
4 days ago | 
terra.com.br | Amina Niasse
O novo presidente-executivo do UnitedHealth Group, Steve Hemsley, prometeu nesta segunda-feira reconquistar a confiança dos acionistas após a recente frustração com os resultados financeiros da companhia. O executivo disse que a empresa está analisando suas abordagens em relação às tendências de custos médicos e à forma como projeta seu desempenho futuro. Hemsley substituiu Andrew Witty como presidente-executivo em maio, após o primeiro resultado abaixo do esperado da empresa desde 2008.
-
4 days ago | 
marketscreener.com | Amina Niasse
Published on 06/02/2025 at 11:51, updated on 06/02/2025 at 15:44 NEW YORK (Reuters) -UnitedHealth Group's new CEO Steve Hemsley on Monday told shareholders he was determined to earn back their trust after its surprising earnings shortfall earlier this year, saying the company was evaluating trends in medical costs and how that will affect its future performance. Hemsley replaced Andrew Witty as chief executive in May after the company's first earnings miss since 2008.
-
4 days ago | 
marketscreener.com | Amina Niasse
Published on 06/02/2025 at 11:51, updated on 06/02/2025 at 12:23 NEW YORK (Reuters) -UnitedHealth Group's new CEO Steve Hemsley on Monday vowed to earn back shareholder trust after its recent earnings shortfall, saying the company was examining its approaches to medical cost trends and how it forecasts future performance. Hemsley replaced Andrew Witty as chief executive in May, following the healthcare company's first earnings miss since 2008.
-
4 days ago | 
today.westlaw.com | Franklin Paul |Amina Niasse |Bill Berkrot |Sriparna Roy
NEW YORK (Reuters) -UnitedHealth Group's new CEO Steve Hemsley on Monday vowed to earn back shareholder trust after its recent earnings shortfall, saying the company was examining its approaches to medical cost trends and how it forecasts future...
-
6 days ago | 
terra.com.br | Amina Niasse
A plataforma de telessaúde Hims & Hers cortará 68 funcionários, ou cerca de 4% de sua força de trabalho, à medida que se ajusta à proibição dos EUA de fabricar cópias em massa do medicamento para perda de peso Wegovy. A proibição da Food and Drug Administration (FDA) dos EUA de cópias compostas do Wegovy, fabricado pela Novo Nordisk, entrou em vigor em 22 de maio. Desde então, as ações da Hims caíram 14%. A empresa confirmou os cortes de empregos em um comunicado na sexta-feira.
-
1 week ago | 
kfgo.com | Amina Niasse
By Amina NiasseNEW YORK (Reuters) -Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk, took effect on May 22. Hims shares have since dropped 14%.
